|
|
||||||||||||||||
How can expensive antiretroviral therapy be best prioritised in under-resourced health systems? In Malawi, targeting laboratory-based tests that measure the progress of the disease may offer one solution to help target those most in need. Almost one million people suffer from HIV or AIDS in Malawi. By March 2004, only three percent of Malawians who needed antiretroviral therapy (ART) were receiving it. Plans to increase the number to 80,000 (50 percent of those needing treatment), will need to ensure that the most urgent cases are effectively targeted. A laboratory test, known as the CD4 test, is often used to decide when someone needs ART treatment. The test is a "proxy" for the state of the body's capacity to defend itself against infections. A CD4 count under a threshold level of 350 cells per unit of measurement (microliter, ul) is considered a low level and the body is less able to defend itself against infections. ART treatment is then considered necessary. However, the CD4 test is expensive and high-tech. The World Health Organisation recommends that in poor countries ART should be given to everyone who has reached stage III and IV of the disease. Médecins sans Frontières and the Ministry of Health of Malawi carried out a study to find out whether all people in stage III and IV did in fact need ART. Receiving ART too soon could mean that the body becomes resistant to the drugs and the treatment is no longer effective when the patient most needs it. In addition there is the inconvenience of taking the tablets, of possible side effects, and the need for follow-up visits to the hospital. The study was carried out in Thyolo district, a rural part of southern Malawi, between April 2003 and January 2004. Everyone over the age of 13, who attended the district hospital with AIDS stage III or stage IV, was included in the study. The study found that out of the 401 people studied:
The study recommends that, while it is not possible to offer everybody CD4 testing:
While targeted CD4 testing may not identify all those with high CD4 counts, it does prevent a considerable number of people from receiving early ART treatment thus saving unnecessary costs associated with ART. In Malawi, the saving could be as much as two million US dollars per year. Source(s): Funded by: Médecins sans Frontières id21 Research Highlight: 16 March 2006
Further Information: Tel:
+352 332515
Anthony D. Harries Tel:
+265 1 795054 Other related links:
|
|
|||||||||||||||
|
|
|
|
|
|
||||||||||||